7 days in healthcare (October 17th-23rd, 2022)



From the point of view of biomedicine, the announced “vaccine against cancer” should be highlighted, which could be prepared before 2030. Although not strictly a vaccine, it represents a promising treatment against this disease based on mRNA technology, the same used for covid vaccine.

Regarding Global Health, an important announcement by the WHO about the dangers of a sedentary lifestyle, which could produce 500 million chronic patients in 2030. The WHO dedicates 2,600 million in its next strategy 2022-2026 for the eradication of polio .

Regarding international health policy, an important debate introduced by The Economist on the massive use of antidepressants, when only in 15% of cases do they have an effect other than placebo. Opioids in the United States and antidepressants worldwide are examples of the misuse of medications, which can lead to, and in many cases lead to, health problems. The post-pandemic horizon has generalized a hybrid work model (face-to-face and online) for office professionals.

If we talk about national health policy (Spain), the pressure on hospitals due to covid remains low, despite a slight rise in this disease. Intense debate on the flight of Spanish doctors to other countries, attracted by better salary and professional conditions. No matter how much the number of MIR vacancies and Faculties of Medicine increases, the problem will not be solved if working conditions are not acted upon. Teleconsultations seem to consolidate in Primary Care, already being more than 50% of the visits. The Trans law is the subject of great controversy. Most psychiatrists and psychologists, against. Obviously, we are in favor of the position of the WHO by removing from the list of diseases already in 2018 these cases of having a gender identity other than biological sex and wanting to change the morphology of their body. We welcome that there is a law on the subject as in most Western civilized countries. But one thing is that and another that 14-year-olds can choose sex without a psychological evaluation carried out by experts, who can rule out cases. Irreversible problems may occur. There is a certain consensus that the current wording of the law does not sufficiently protect minors.

In the field of companies, at the international level, we must welcome the first agreement with a pharmaceutical company (Novartis) to produce an anticancer drug as a generic that is still protected by patent, for its production in developing countries. As far as Spain is concerned, the continuous growth of health insurance should be highlighted, which in 2022 until September grows considerably more than the insurance as a whole.


Global Health

International health policy

National health policy


Roche: how to run a big pharma like a startup (Breakfast-debate with Mr. Federico Plaza, Director of Corporate Affairs of Roche Farma Spain)


Roche: how to run a big pharma like a startup

Breakfast-debate with Mr. Federico Plaza, Director of Corporate Affairs of Roche Farma Spain



On April 27, 2022, a breakfast-debate was held at the Roland Berger headquarters in Madrid with Mr. Federico Plaza, Director of Corporate Affairs of Roche Farma Spain and Vice President of Farmaindustria. What follows is no more than a brief summary of the content of that breakfast.

A little history

Roche was founded in Switzerland by Fritz Hoffmann-La Roche in 1896, more than 125 years ago. It was born as a laboratory of individualized master formulas, but very soon it became a pioneer company in the development and industrial manufacture of chemically synthesized medicines to promote accessibility for all patients to medical advances.

The company is today at the forefront of personalized medicine thanks to its commitment to advanced therapies, precision diagnosis and data analysis sciences. This focus on personalized precision medicine has somehow brought Roche back to its roots, focusing on personalized treatment.

Another of the keys to Roche’s history is that, at the beginning of this century, it was able to combine the two company concepts that existed until then: that of the so-called big pharmas (based above all on the development of chemically synthesized drugs each directed of them to millions of patients, the well-known blockbusters) and biotechnological companies (which research and develop biological therapies, whose active ingredient is derived from organic substances).

Roche helped blur that difference with the 2009 acquisition of Genentech, a major US biotech company, in what was at the time the largest takeover by a Swiss company. Now all the big pharmaceutical companies are biopharmas.

Roche has continued to work in this line in recent years, having fully entered the 21st century in the development of new therapies based on molecular biology and the use of data analysis sciences through new big data tools and artificial intelligence.

The numbers of a giant

The numbers for Roche, the world’s largest biotech company, are staggering. Both divisions (Pharmaceutical and Diagnostics) showed the following figures in 2020:

  • 800 million Swiss francs in sales.
  • 900 million Swiss francs of net profit.
  • 700 million francs invested in R&D, the highest figure in the entire industry, which represents 22% of turnover.
  • 80 molecules in clinical development that cover a wide range of pathologies (oncology, hematology, neuroscience, ophthalmology, rare diseases, etc.), of which 70 are present in Spain.

A new company model

The digitization process, the progress in the personalization of treatments and the Covid pandemic have accelerated the transformation process in which the company was already immersed to anticipate the future and work to achieve solutions for the health problems of patients in the future. One of the keys to this transformation is the change in the business model, transcending the traditional role of companies as mere providers of medicines to a new role as an ally of the system when it comes to achieving comprehensive solutions to the demands of health systems and patients, in measurable terms in health outcomes.

Within this process Roche considers some significant strategic changes.

Main strategic changes

There are eight fundamental strategic changes that Roche is implementing globally and, specifically, in Spain, one of the countries where this transformation is most advanced:

1. Not having medical visit networks

Roche no longer has networks of medical representatives in Spain, with a single commercial vocation. It has replaced them with scientific networks, whose interaction with the health system is totally different, activating co-creation projects with clinicians and managers, in order to give more value to the treatment of patients and respond collaboratively to the challenges of health systems.

Consequently, Roche professionals no longer have sales incentives, but their variable depends on more qualitative indicators and always based on their ability to favor collaborative projects and solutions always based on science.

2. A much more horizontal structure

The traditional way of operating big pharma is through a heavy bureaucracy, with a very slow and hierarchical decision-making process. In this way, any decision had to go through different people and levels of the company before becoming a reality.

The new Roche is based on a much more horizontal structure, where all professionals are empowered to make decisions in their field, and where leaders are fewer and have a more inspiring and strategic role, going beyond the role of traditional leadership.

3. No local budget

Of course, the company works with a budget at the global and European level, but not at the country level. The situation based on local budgets and the need to make quarterly reports, as befits a listed company, meant that many resources were devoted to explaining what is done to the parent company. For this reason, around 30% of the effort was spent not so much on promoting new projects, but on preparing the entire quarterly reporting exercise.

This has changed and, since last year, the Spanish subsidiary no longer has a budget in the traditional format.

4. Agile methodology

Compared to the traditional model where a boss is in charge of assigning tasks to collaborators, telling them how to do them and waiting for a desired result, Roche has established the agile methodology, which gives employees autonomy when making decisions, encourages their initiative and stimulates their ability to propose new projects. The role of the hierarchical superior changes and goes from being a boss to a VACC leader: Visionary, Architect, Coach and Catalyst. It is a model that also truly puts the customer at the center through multifunctional and self-organized teams that work collaboratively.

5. Bet on R&D

In the last financial year, Roche spent 13.7 billion Swiss francs on R&D, 22% of turnover. All of Roche’s plans include reinforcing R&D-oriented resources, until this figure doubled, reaching 20,000 million Swiss francs in 2030. In Spain, Roche is a leader in biomedical R&D: it carries out more than 300 clinical trials every year in 180 hospitals in which more than 1,100 researchers and almost 15,000 patients participate.

6. OneRoche

Roche has two major business units: the Pharmaceutical Division (Roche Pharma) and the Diagnostics Division (Roche Diagnostics). Even within the Diagnostic Division, the Diabetes area (Roche Diabetes Care) was segregated. Although they will continue to be two separate business units, the advancement of personalized precision medicine brings diagnosis much closer to treatment and vice versa, which is why the company is working so that both divisions work closely in coordination to offer comprehensive solutions that bring together precision diagnosis, advanced therapies and data analysis.

7. From 3 to 5, 50% reduction in costs for the system

The company works with a strategic objective for this decade: to be able to provide three to five times more medical advances at a 50% lower cost for society. One of the keys to achieving this is to improve the efficiency of R&D thanks to the use of new digital and data management tools, which are already allowing a shortening of clinical research deadlines and the development of tools such as approvals conditions, which speed up the arrival of innovations on the market, which also allows a reduction in costs.

8. The data heals

Precisely for this is Data Analytics, which is not a Roche business area, but tries to strengthen collaboration with the system.

The new paradigm of personalized medicine will only be possible if it is based on the development of new tools for managing enormous amounts of clinical data (big data) and the real life of individuals (real word data) through artificial intelligence applications and machine learning. That is why the development of health data management tools (data analytics), both individually and in aggregate, will be one of the keys to the immediate future for Roche.

In short: invest better to be more productive

This is what Roche intends: to invest better in an increasingly efficient biomedical R&D process, which entails lower costs for the system and provides more value, measurable in health outcomes, both to patients and health systems.

7 days in healthcare (April 25-May 1, 2022)



From the point of view of biomedicine, to highlight the evolution of acute hepatitis in children; Lilly’s announcement of a drug to tackle obesity that could compete with bariatric surgery; and the analysis of the New England Journal of Medicine on the “boosters” for covid.

As far as Global Health is concerned, we again quote Bill Gates, who is publishing a new book on pandemic prevention. Great concern about the resurgence of measles, yellow fever and polio in Africa, due to the low levels of vaccination against these diseases, given that resources have been largely diverted to covid.

As for international health policy, the problems of the “zero-covid” policy in China continue, which threatens the global economy, due to the closure of the largest port in the world: Shanghai. It seems increasingly clear that for political reasons this “zero-covid” approach will not change until the approval of a third term for its leader Xi. Also noteworthy is the very serious discrediting of the National Health Service in the United Kingdom, which until now had been the object of almost religious veneration.

If we talk about national health policy (Spain), the incidence of covid continues to increase, particularly in some regions (Galicia, Navarra, Asturias and Castilla y León). The Health Advertising Law was not approved by Parliament, which is not necessarily bad news, since it was largely part of the confrontation between the College of Dentists and the dental care networks. The announced strike of doctors in Madrid, regardless of its results, has its origin in a very serious problem: the very high rate of temporary employment (more than 50% of doctors in the public system in Madrid). Very interesting statements by José Ramón Repullo, proposing national accreditation and hiring at the local level.

In the field of companies, from the international point of view, certain possible disruptive changes for the pharmaceutical industry should be highlighted: 3D printing, which would allow the “manufacturing” of medicines in a clinical environment; and the movements of Amazon for the sale of prescription drugs.


Global Health

International health policy

  • COVID-19

o Serious problems continue in China with the “zero-covid” policy. The general impression is that the rhetoric of war does not help to defeat covid ( covid), while the global economic implications of the closure of Shanghai persist, the largest port in the world (

o The “zero-covid” policy in China, a great personal bet of the leader Xi and difficult to be modified before his re-election for a third term ( 4a76-9b81-d561deaabc5c)

o Covid cases on the rise in virtually all of the United States (

  • Other issues

o The FDA, about to ban menthol cigarettes. They are the most used among the black population (

o Very serious loss of prestige of the National Health Service, which is ending an almost religious adoration of this body in the United Kingdom. A survey says that global satisfaction dropped to 36%, something never known. Poor staff planning among major problems (

National health policy (Spain)


o The cumulative incidence among people over 60 years of age continues to rise, reaching (April 29) 676.43 cases per 100,000 inhabitants in the last 14 days, an increase of almost 70 points compared to the previous measurement. Occupation rate due to covid: 5.12% in the ward and 3.66% in the ICU ( deceased-ia-exceeds-676-points_113987_102.html)

o The Ministry of Health reports almost 2,000 deaths in April, the first full month of “flu” from covid ( flu-covid/668683313_0.html)

o Increase in the incidence of covid grows by 35% after Easter and there are already four regions with the unbridled incidence (Galicia, Navarra, Asturias and Castilla y León) ( /revenues-covid-semana-santa-ccaa-incident-runaway/668183406_0.html)

o The Ministry of Health will authorize the fourth dose for those over 80 years of age and those who live in residences, a total of about 3 million people ( fourth-dose-vaccine-covid-older-80.html)

  • Regulatory announcements

o The Health Advertising Law presented by the PP fails, which is regretted by the professional associations, in particular that of dentists. Apparently, the Government is preparing a Royal Decree on the subject (

  • Other issues

o Madrid hospital doctors go on strike over temporary contracts (

o Interesting statements by José Ramón Repullo regarding the temporality of doctors and health professionals and their non-solution through the OPEs. He proposes national accreditation and contracting by centers, as exists in other countries ( -of-a-bad-system-worse-governed.html)

o Cases of severe hepatitis in children in Spain rise to 22 (

o 700,000 Spaniards on the surgical waiting list, the worst figure in the history of public healthcare ( html)

o Núñez Feijóo calls for the creation of the emergency specialty, with the argument of preventing primary care professionals from leaving (

o Facme presents the Spanish recertification model (

o Five communities (Extremadura, Aragón, Baleares, Comunidad Valenciana and Navarra) ask AIReF to evaluate their healthcare and pharmaceutical spending ( the-airef-assess-your-health-care-and-pharmaceutical-expenditure)

o Very interesting article by José Luis Puerta: “Data saves lives”, on the need to overcome the situation in which the custodians of the data are not capable of exploiting them, nor do they allow third parties to do so (https://www.diariomedico .com/opinion/data-saves-lives.html)


  • International News

o Possible disruptive changes for the pharmaceutical industry ( volumetric 3D printing that would allow drugs to be “manufactured” in a clinical setting ( and Amazon Prime’s offer to facilitate basic drugs for $1 a month (

o Roche sales soar in the United States due to the demand for covid tests (

o Investors pressure Nestlé and Kraft Heinz to target health (

o Philips records losses of 151 million euros in the first quarter of 2022 ( -first-quarter-of-2022.html)

o Abbie strengthens its neurosciences portfolio and acquires Syndesis Therapeutics (

  • National News

o Lácer attracts the interest of venture capital funds (

o Grifols closes the purchase operation of its German rival Biotest (

o Faes Farma profit grows 24% thanks to licenses and the Latin American market ( -a-24-thanks-to-the-licenses-and-the-latin-american-market.html)

o Senniors disembark in Abu Dhabi with the support of the country’s sovereign wealth fund ( -country.html)

o Quirónsalud launches a new rehabilitation center in Ronda de Triana ( -triana.html)

o Hospitales Parque (CASER) accelerates in 2021 and raises its income by 46%, up to 58 million euros ( -46-your-income-up-to-58-million-euros.html)

o Asisa strengthens Otoaudio and opens its first center in Seville (

o Asisa Dental opens its first own clinic in the Canary Islands in Las Palmas (







7 days in healthcare (March 21-27, 2022)



From the point of view of biomedicine, the progress in the treatment of breast cancer should be highlighted, according to the article published by the NEJM, with a brake of around 80% of this advanced cancer and makes it disappear in 16%. .

As far as Global Health is concerned, there are undiagnosed cases of tuberculosis (the missing tuberculosis), a disease that continues to have 10 million new cases a year and causes 1.5 million deaths. The Lancet report on what needs to be done to meet target 3.4 of (on non-communicable diseases) of the Sustainable Development Goals. Inequality in covid vaccination and its possible ways to solve it are the subject of an analysis by the NEJM. Concern for the health of the 3.5 million refugees from Ukraine. The low mortality of covid in Africa, a continent that was thought could be devastated by this disease, remains a mystery.

As for international health policy, the debate continues on the covid-zero policy in China, which has achieved great results so far (both in terms of mortality and economics), but it is not known if it will be able to continue with the variant “omicron”. The WHO judges the lifting of COVID measures in Europe too premature, considering that cases are growing, among other countries, in the United Kingdom, Ireland, Greece, France, Italy and Germany.

If we talk about national health policy (Spain), we are witnessing a relaxation of the measures against covid, despite its upward trend in recent days. Arrival of Paxlovid, Pfizer’s treatment for severe cases of covid. The important report published by the Catalan Society of Health Management, with an exceptional team led by Jordi Varela, on the forms of contracting health services from the point of view of value, is very noteworthy. The deans of Medicine react to the Ministry’s announcement of the increase in the “numerus clausus” in medicine by 10%.

In the field of companies, it is worth highlighting the evolution of the purchase of the fertility company IVI, the largest operation carried out by private equity companies in healthcare in Spain and with a company valuation of around 2,500 million euros.








7 days in healthcare (March 7-13, 2022)



From the point of view of Biomedicine, the Lancet report on risk factors in COPD (chronic obstructive pulmonary disease), one of the great burdens of all health systems, should be highlighted. Also the finding that COVID can cause brain damage, although its scope is yet to be determined.

As for Global Health, it is worth noting the WHO complaint that 16 health facilities have been attacked in the war in Ukraine, as well as the organization’s statement that women should have access to safe abortions, to avoid mortality as well as hospitalizations due to complications.

When it comes to international health policy, the advice for the next pandemic contained in a major editorial in the Financial Times is important. There would be three priorities: 1. Reduce the risk of the appearance of a new pathogen (controlling the markets where animals are sold, for example); 2. Prevent it from spreading throughout the world; and 3. Develop an effective weaponry with vaccines and treatments as soon as possible. The incidence of COVID is increasing in England and France, just as the outbreak in China is the largest since the initial one in Wuhan. A report by The Lancet analyzes the mortality from COVID by country and even (as in the case of Spain) by region in the different countries. Spain is among the nations with the highest mortality from COVID per number of inhabitants. In the United Kingdom, a conservative think tank, with the support of the British Secretary of Health, proposes that primary care physicians become primarily salaried, thus breaking one of the fundamental elements of the political pact that gave rise to the NHS (on the one hand, hospitals are nationalized, but, on the other, the consideration of primary care physicians as independent mini-entrepreneurs is respected).

In national health policy, it is found that the drop in the incidence of COVID stagnates in Spain. Private healthcare, through the IDIS Foundation, considers the interoperability of the clinical history of private healthcare patients, regardless of insurer or provider.

Of the activity of the companies, an analysis of the Financial Times comments on how the economy of the pharmaceutical companies works against the development of antibiotics. Europe has lost the race against the United States in the development of new drugs. Important publication of the Roche Institute of a manual on personalized medicine aimed at health professionals.





o Lessons for the next pandemic, after two years of covid, an important Financial Times editorial. Three priorities: 1. Reduce the risk of emergence of a new pathogen; 2. Prevent it from spreading throughout the world; and 3. Develop an effective weaponry with vaccines and treatments as soon as possible (

o The COVID pandemic has lasted two years. Next steps may be divisive (

o The covid does not decrease, but increases, in France ( -rebond-de-l-epidemie_6117120_3244.html)

o Covid cases and hospitalizations on the rise in England (

o China, fighting the largest outbreak since Wuhan (

o Chinese scientists, in search of an alternative to the “zero COVID” policy, which the Chinese government boasts so much about (

o Where did the 5 “Trillion” (American) dollars of Covid stimulus go(

o Mortality from COVID, three times higher than official figures (, according to a major report by The Lancet (

o Austria suspends the first universal vaccination obligation (

  • Other topics

o The pandemic has accelerated the demand for private healthcare services in the UK (

o The NHS app should be the new ‘gateway’ to the NHS, says UK health secretary (

o British primary care physicians should be primarily salaried (, says a report by a conservative think tank (



o The drop in infections stagnates in Spain, with the incidence still at high risk, with 430.1 cases per 100,000 inhabitants, far from 50 (

o Sánchez announces that the mandatory indoor mask will soon be abolished (

o Spain destroys more than a million vaccines against covid, most of them from Janssen and AstraZeneca (

  • Political announcements

o Congress backs the proposal of the political party Ciudadanos for a law on ALS (

  • Other themes

o The Valencian health system carries out almost 600 sex change interventions in five years (

o 9,932 candidates will be able to choose a MIR position (

o The IDIS calls for more accessibility in Oncology (

o Change in the General Directorate of Farmaindustria (

o The Royal National Academy of Medicine joins the European Academies of Medicine with a declaration on Ukraine (

o Private healthcare invests 1.3 million euros to give private healthcare patients access to digital medical records in 2023 (


  • International News

o The Sacklers will pay $6 billion for Purdue’s opiate lawsuits (

o Kirin goes beyond beer and goes into healthcare (

o How Pharmaceutical Economics Holds Back Antibiotic Development (

o Europe loses the battle against the USA and only develops 22% of new medicines (

o Sanofi acknowledges that they were late for the covid vaccine (

  • National News

o Korian: 60 new beds and more purchases to bill one hundred million euros in Spain (

o Europe asks HIPRA to expand its clinical trial of the covid vaccine (

o The Roche Institute publishes a personalized medicine manual for healthcare professionals (




7 days in healthcare (1-7 november, 2021)




From an international point of view, to highlight something we knew: that WHO, in its current configuration, is not prepared for global health challenges. However, this finding is important in the article in the British Medical Journal by Anthony Costello. Europe, once again in the center of expansion of the pandemic. The decision of the North American Democrats to reduce the price of medicines, via the negotiation in Medicare, is very far-reaching. This decision, if applied, will have major consequences for the entire pharmaceutical industry globally.

At the national level, to highlight the article in The Lancet, which says that Spain could have achieved group immunity. For the rest, the incidence of COVID continues to grow in our country, although it does not reach, by far, those of other European countries. Waiting lists are a big concern throughout Spain. Controversy over the new Equity, Universalization and Cohesion Law. Podemos wants to take advantage of it to repeal Law 15/1997, which allows the outsourcing of health services.

As a business activity, to highlight the two new antivirals against covid-19, one from Merck and the other from Pfizer. Merck has released the patent so that it can be used widely in developing countries. Novartis dissociates itself from Roche, selling it its 33% stake in the latter company.


  • The WHO, in its current configuration, is not ready for its purpose, but is limited by lack of funds and political interference, and this has been demonstrated in this pandemic that has produced more than 18 million deaths, writes the economist Anthony Costello in the British Medical Journal (BMJ, 3 Nov 21)
  • Europe once again at the center of the covid pandemic, says WHO, (The Guardian, 4 Nov 21)
  • The WHO warns of the increase in deaths from covid in 56 countries, and insists that vaccine manufacturers have not done their job well (ConSalud, 5 Nov 21)
  • Democrats in the United States reach an agreement to reduce the price of drugs, allowing the government to negotiate the price of Medicare drugs. The United States pays three times more for many drugs than Europe, according to a study by the Brookings Institution. Initially, the measure will be launched with the 12 most expensive drugs (FT, 2 Nov 21)
  • The fourth wave continues to beat the record of infections in Greece, with almost 7,000 daily (El Confidencial, 6 Nov 21)
  • Excess mortality grows in Russia, since the beginning of the pandemic (FT, 2 Nov 21)
  • The management of the pandemic leaves a trail of investigated political leaders: Brazil, France, Italy, Austria, India, … (El Debate, 2 Nov 21)
  • India’s successes against covid are analyzed: more than half of Indians have received at least one dose of the vaccine. 6 million are vaccinated every day (The Economist, 29 Oct 21)



  • The Lancet suggests that Spain could have achieved group immunity. They are based on the high infections and the high percentage of vaccination (La Razón, 3 Nov 21)
  • The incidence of covid rises more than two points, to 53.7 cases per 100,000 inhabitants (El País, 5 Nov 21)
  • Madrid for the first time exceeds half a million patients to see the specialist. Experts warn that the pandemic has generated in Spain a dammed demand that will emerge in the coming semesters (El País, 5 Nov 21)
  • Spain, one of the five countries in which Covid-19 caused the greatest loss in life expectancy, according to a study published by the British Medical Journal (ABC, 3 Nov 21)
  • The Health Ministry sells a million vaccines to Australia, New Zealand and Paraguay, before they expire (El Español, 2 Nov 21)
  • The WHO requests to increase oral public coverage in Spain (Health Act. The proposal receives the support of the General Council of Dentists (Health Act, 5 Nov 21)
  • Podemos will not support the Darias Equity Law. The Ministry wants to promote a Law of Equity, Universality and Cohesion and Podemos does not support it by not repealing Law 15/1997, which allows the outsourcing of health services (ConSalud, 5 Nov 21)
  • The Health Ministry seeks location for its strategic reserve of covid material (El Periódico de España, 5 Nov 21)



  • Merck drug effective to treat covid-19. The drug is an oral antiviral, called molnupiravir, and has already been approved by the British Agency. It has been launched by Merck and Ridbback Biotherapeutics, a Florida-based biotech. The drug is indicated for the unvaccinated and for those vaccinated who develop the disease. The treatment will be worth US $ 700 in developed countries. Merck will allow the development of generics in 105 countries (The Economist, 4 Nov 21)
  • Alphabet, Google’s parent company, launches an AI company, Isomorphic Labs, for the discovery of new drugs. It will work together with DeepMinds, Google’s AI company (FT, 4 Nov 21)
  • Pfizer increases the sales forecast of its covid vaccine in 2021 to 36,000 million US $ (FT, 2 Nov 21)
  • Biogroup, a bioanalysis group piloted by Stéphane Eimer and with a presence in Belgium, Luxembourg and the United Kingdom, enters the Iberian Peninsula with the purchase of Cerba Internacional and Analiza (both owned by Marcelo Weisz). ASISA will retain its 50% stake in Analiza (Les Echos, 4 Nov 21)
  • Novavax, a protein-based American covid-19 vaccine, receives its first approval in Indonesia. May promote immunization in developing countries. An application for authorization has also been sent to Canada, the United Kingdom and the European Union (FT, 1 Nov 21)
  • Pfizer announces an antiviral pill (Paxlovid) that prevents 89% of hospitalizations and deaths from covid (El País, 5 Nov 21)
  • The Valencian government will propose to the Data Protection Agency a sanction to Ribera for withholding data from the Torrevieja hospital (, Nov 4 21)
  • Centene closes the year of the coronavirus with losses in its health adventure in Spain (Nov 6, 21)
  • “Son Espases”: the macro-investigation on the concession to OHL of this hospital in the Balearic Islands, which links the Balearic Islands with the illegal financing of the PP (, Nov 5, 21)
  • Novartis sells its 33% stake to Roche for more than US $ 20 billion. A relationship of more than twenty years between the two companies is ended (PlantaDoce, Nov 4, 21)
  • MD Anderson launches a clinical trials unit (PlantaDoce, 3 Nov 21)
  • Eugin expands through Canada and acquires the fertility centers of Trio Fertility (PlantaDoce, 2 Nov 21)
  • Affidea, a European provider of diagnostic imaging, outpatient services and cancer care, expands in Spain and Northern Ireland with two new acquisitions (PlantaDoce, Nov 3, 21)
  • The biotechnology company of Spanish origin Aura Biosciences, jumps to the Nasdaq (PlantaDoce, 3 Nov 21)
  • Rovi doubles its profit in the first nine months of 2021, to 99 million (PlantaDoce, 3 Nov 21)